Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001209191-16-130970
Filing Date
2016-07-05
Accepted
2016-07-05 16:18:06
Documents
2
Period of Report
2016-07-01

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 1568
2 POA DOCUMENT poa.txt EX-24.3_665107 3065
  Complete submission text file 0001209191-16-130970.txt   6175
Mailing Address C/O SOMAXON PHARMACEUTICALS, INC. 10935 VISTA SORRENTO PARKWAY, SUITE 250 SAN DIEGO CA 92130
Business Address
Onaitis Matthew (Reporting) CIK: 0001362822 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-36912 | Film No.: 161750687

Mailing Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121
Business Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121 858-752-6170
Cidara Therapeutics, Inc. (Issuer) CIK: 0001610618 (see all company filings)

EIN.: 461537286 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)